Using the adherence‐efficacy relationship of emtricitabine and tenofovir disoproxil fumarate to calculate background hiv incidence: a secondary analysis of a randomized, controlled trial-Reference-Cited by-同舟云学术

Using the adherence‐efficacy relationship of emtricitabine and tenofovir disoproxil fumarate to calculate background hiv incidence: a secondary analysis of a randomized, controlled trial

Published:2021-05 Issue:5 Volume:24 Page:
ISSN:1758-2652
Container-title:Journal of the International AIDS Society
language:en
Short-container-title:J Int AIDS Soc

Author:

Glidden David V¹²,Das Moupali³,Dunn David T⁴^ORCID,Ebrahimi Ramin³,Zhao Yongwu³,Stirrup Oliver T⁴,Baeten Jared M³,Anderson Peter L⁵

Affiliation:

1. School of Medicine University of California San Francisco San Francisco CA USA

2. Department of Epidemiology and Biostatistics San Francisco CA USA

3. Gilead Sciences Inc. Foster City CA USA

4. Centre for Clinical Research in Infection and Sexual Health Institute for Global Health University College London London UK

5. University of Colorado Denver ‐ Anschutz Medical Campus Aurora CO USA

Funder

Gilead Sciences

Publisher

Wiley

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jia2.25744

Reference44 articles.

1. Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men

2. Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women

3. On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection

4. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial

5. Preexposure Prophylaxis for HIV Prevention in a Large Integrated Health Care System: Adherence, Renal Safety, and Discontinuation

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HIV Prevention Among Men Who Have Sex With Men: Tenofovir Alafenamide Combination Preexposure Prophylaxis Versus Placebo;The Journal of Infectious Diseases;2023-11-16

2. Estimating counterfactual placebo HIV incidence in HIV prevention trials without placebo arms based on markers of HIV exposure;Clinical Trials;2023-10-25

3. Efficacy estimates of oral pre-exposure prophylaxis for HIV prevention in cisgender women with partial adherence;Nature Medicine;2023-10-05

4. Control groups for HIV prevention efficacy trials: what does the future hold?;Current Opinion in HIV and AIDS;2023-09-11

5. Interpretation of active-control randomised trials: the case for a new analytical perspective involving averted events;BMC Medical Research Methodology;2023-06-26